INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are a structurally diverse family of compounds that are effective in the prevention of colorectal cancer (1, 2) . Acetylsalicylic acid (ASA), commonly known as aspirin, is the archetype of the NSAID family. Epidemiological studies have reported an inverse relationship between ASA use and the incidence of colorectal cancers (3, 4) . Animal models have confirmed that administration of various NSAIDs results in fewer tumors (5, 6) .
Nitric oxide-donating NSAIDs (NO-NSAIDs) are novel compounds in which a NO-donating group is attached to the NSAID through a linker molecule. The rationale is that the NO-moiety may diminish or alleviate undesirable NSAID-induced side-effects such as gastropathy (7, 8) . NONSAIDs also share many pharmacological properties with their parental molecules and may possess greater efficacy as chemopreventive agents (7, 8) . NO-ASA is the most potent NO-NSAID reported to date, demonstrating at least 100-fold more activity than other NO-NSAIDs in diverse experimental systems (9) (10) (11) (12) . It is also more effective than aspirin at reducing tumorigenesis in rodent models of cancer (13) (14) (15) (16) .
The DNA mismatch repair (MMR) pathway recognizes and repairs nucleotide mispairs generated by post-replication misincorporation and genetic recombination between heteroallelic DNAs, as well as several DNA damage-specific lesions (17, 18) . There is compelling evidence that links mutations in the MSH2, MSH6, MLH1 and PMS2 genes with Lynch syndrome/hereditary nonpolyposis colorectal cancer (LS/HNPCC) (19) . Tumor tissues from most LS/HNPCC cases associated with MMR defects display microsatellite instability (MSI) (20) . The mechanism of tumorigenesis has been linked to the mutator phenotype conferred by MSI, which provides the environment for the accumulation of multiple secondary mutations that drive tumorigenesis (21) .
ASA suppresses the MSI mutator phenotype of MMR-deficient human colon tumor cell lines (22, 23) via a genetic selection that appears to enhance apoptosis in critically unstable cells. The long term outcome is a cell population that has a persistent deficiency in MMR but paradoxically has acquired a largely microsatellite stable (MSS) phenotype (22, 23) . NO-ASA also suppresses ) that recapitulates the intestinal-specific disruption of Msh2 function (24) . ASA (400 mg/kg) and low dose NO-ASA (72 mg/kg) increased the life span of the LS/HNPCC mice.
Increased survival by NO-ASA occurred at a tenfold lower equimolar dose than that by ASA.
However, dietary exposure of mice to 720 mg/kg NO-ASA, an equimolar dose to 400 mg/kg ASA, as well as 1500 mg/kg NO-ASA accelerated intestinal tumorigenesis uniquely in MMR-deficient LS/HNPCC mice. This study suggests the long-term use of ASA in LS/HNPCC and should also enable reconsideration of NO-ASA structure such that higher doses, greater efficacy and reduced toxicity may be accomplished.
METHODS

Generation of mice
The development and subsequent characterization of the LS/HNPCC mouse model used in (GTC AGT CGA GTG CAC AGT TT); IMR1878 (GTG TGG GAC AGA GAA CAA ACC); IMR1879   (ACA TCT TCA GGT TCT GCG GG). Primers IMR0015/IMR0016 amplified a 200 bp product, indicative of the endogenous wild-type allele. Primers IMR1878/ IMR1879 yielded an 1100 bp product, indicative of the villin promoter-Cre (VpC) transgene. The VpC control mice were obtained from The Jackson Laboratories (strain B6.SJL-Tg(Vil-cre)997Gum/J) and were genotyped as above.
Animals were bred in a barrier one facility and were maintained according to the NIH animal care and use guidelines. All experiments involving animals received prior approval from the OSU Institutional Animal Care and Use Committee.
Drugs and treatment groups
Acetylsalicylic acid was obtained from Sigma.
The these conditions, in addition to lethargy for >24 hours, unresponsiveness to stimuli, or anorexia for >24 hours, such mice were sacrificed and a complete pathological examination performed. Starting at 6 months, all animals were weighed weekly. Weight loss of >20% resulted in removal of the animals from the study for subsequent pathology. If a consensus opinion could not be reached about a particular animal's health, the attending veterinarian was consulted.
Tumor analysis and histopathologic classification
All animals in the study were subject to criteria for early removal, and were euthanized by CO2 asphyxiation, followed by cervical dislocation, for pathological examination before they died from tumor-associated complications. Mice were examined for the presence of tumors. Intestinal tumors were examined macroscopically and with a dissecting microscope. Tumor number and location were recorded. Tissues were fixed in 10% formalin, embedded in paraffin and 4 µm sections were cut for slides. Sections were stained with hematoxylin and eosin according to standard protocols. A trained pathologist evaluated the slides.
PCR analysis of MSI
The mouse primers used for MSI analysis have been reported previously as TG 27 two independent amplification reactions of each microsatellite sequence were examined for each DNA sample. If there was any ambiguity about the outcome, the amplification was repeated a third time.
Small-pool PCR analysis of MSI was performed in a similar manner, except that ~100 pg of DNA was used as a starting template. Forty-eight reactions were performed on each DNA sample from matched sets (n=8) Supplementary Table S2) .
We often found that one marker was largely uninformative. However, this criteria is identical to the NCI definition of MSI (20) . Numbers are expressed as a percentage (in parenthesis) of the total number of tumors analyzed for each group.
Fisher's exact test (two tailed) was used to calculate the significance of comparative changes in MSI between MSI-L and MSI-H tumors from NSAID treated Msh2 flox/flox VpC +/+ mice.
Statistical analyses
All statistical analyses were generated with Graphpad Prism 5.0 software. Survival data from the Kaplan-Meier plots were compared with the log-rank test. Differences in tumor burdens
were compared with the Mann-Whitney U test. Comparative MSI was evaluated with a two-tailed
Fisher's exact test. In all cases a value of P ≤0.05 was considered statistically significant. 1). In contrast, the untreated and 720 mg/kg VpC +/+ control groups survived in excess of 800 days ( Fig. 1) and their median survival times could not be calculated since they were eventually removed from the study to determine tissue MSI and tumor status, if any. Based on previous work (24) , it is evident that the effects of high dose NO-ASA observed in our studies are genotype-specific; only manifesting in the LS/HNPCC mouse model but not wild type mice. These effects appear to be associated with intrinsic pharmacokinetic features of the drug (discussed below). ASA and lowdose NO-ASA regimes increased the survival of LS/HNPCC mouse model by 18-21%.
ASA and NO-ASA treatment affect intestinal tumorigenesis in an LS/HNPCC mouse model
Tumors were confined to the intestines of the LS/HNPCC mice, predominantly in the duodenum and jejunum, and rarely in the ileum ( Table S2 ). The microsatellite profiles of both normal and tumor intestinal tissues remained unstable relative to the MSS patterns of the ear in ASA and NO-ASA treated mice ( Fig. 3; Fig. 4 3A ; Fig. 4A ; Supplementary Table S2) .
ASA may stabilize MSI in the intestinal epithelia of LS/HNPCC mice
Comparative MSI analysis provided a measure of the relative differences in instability between adjacent normal and tumor samples derived from the same tissues. We used the Based on our previous cellular data we expected only a partial suppression of the MSI phenotype, which might cause a shift in the relative levels of MSI-H to MSI-L (22).
High dose NO-ASA induced relative increases in MSI where 94% of intestinal tissues from the 720 mg/kg and 86% of tissues from the 1500 mg/kg treated mice displayed MSI (Table 1) .
Moreover, 75% of tissues from mice receiving 720 mg/kg NO-ASA were characterized as MSI-H, (Table 2; Supplementary Table S2 ). These differences also did not attain statistical significance. However, there was a trend toward MSI stabilization by ASA that is consistent with the cellular studies (22, 23) .
Additional high-resolution MSI analyses were performed by small-pool PCR with marker MSM01 (TG 27 ) on matched (E), (N) and (T) DNAs for a subset of mice in each treatment group.
This enabled a more extensive assessment of the distribution of novel allelic variants at this locus in the microsatellite unstable normal and tumor intestinal tissues. The resulting profiles comprised a representational distribution of the intrinsic allelic diversity within each tissue (Fig. 4) . Ear tissues from these animals were consistently MSS, with the major 137 bp allele always flanked by a (Fig. 4) . Taken as a whole, these observations appear to suggest that the underlying mechanism(s) through which ASA increases animal survival in our LS/HNPCC mouse model is by suppression of MSI. However, additional studies will be required to fully support this conclusion.
DISCUSSION
The role of NSAIDs in the prevention of colorectal cancer is mediated through various mechanisms, including the inhibition of cyclooxygenase 2 (COX-2), and the induction of apoptosis through COX-2 independent pathways (26). Previous studies from our laboratory suggested that ASA partially suppresses the MSI-H phenotype of human colon cancer cell lines through an apoptotic mechanism that appeared to be COX independent (22) . In vitro ASA has been shown to arrest colon cancer cells at the G 1 /S checkpoint, and induce apoptosis through activation of ATM, p21 and BAX (27) . Among NSAIDS, ASA is still a preferred choice for chemoprevention in average-risk individuals. This is not only because of its demonstrated chemopreventive efficacy, but also because of its unique potential in cardiovascular protection (3, 4) .
In this study we investigated the chemopreventive potential of ASA and NO-ASA using a newly-developed mouse model of LS/HNPCC. LS/HNPCC mice treated with ASA at 400 mg/kg had an increased median survival time compared to untreated controls, with ~18% of the mice living to over 500 days (Fig. 1) fold less equimolar dose compared to ASA (Fig. 1) . It is possible that this lowered dose could significantly reduce the gastropathies associated with long-term ASA administration.
ASA and low dose NO-ASA do not completely suppress tumorigenesis. This may be partially a result of our dosage structure, which for ASA was at the lower limit compared to previous colorectal carcinogenesis models (28, 29) . Although LS/HNPCC mice treated with both drugs survive for longer than untreated controls, there was little difference in the eventual tumor numbers (Table 1) The available literature supports the chemopreventive superiority of NO-ASA over that of parental ASA (7, 8) . It has consistently been demonstrated that animal models treated with NO-ASA can tolerate higher doses than ASA, and survive longer with less tumor burden (13) (14) (15) (16) . The decision to administer ASA at 400 mg/kg was based on an earlier study which demonstrated that similarly treated Msh2 -/-mice remained viable for up to a year without any obvious side-effects (29) .
720 mg/kg NO-ASA is equimolar to 400 mg/kg ASA and enables a direct comparison of both compounds at the same effective concentration. These levels of NO-ASA enhanced tumorigenesis in our LS/HNPCC mouse model in a dose-dependent manner. Even though there were significant differences in survival and tumor burden between ASA treated and 720/1500 mg/kg NO-ASA 
accelerated incipient tumorigenesis. Moreover, the decreased survival caused by high dose NO-ASA treatment is genotype-specific for mice with the intestinal Msh2 deletion.
Why does NO-ASA induce genotype-specific tumorigenesis in vivo? NO-ASA survives passage through the stomach intact and is subject to metabolic transformation only after absorption by the gut (33, 34) . The regional increase in tumor formation is likely related to the uptake of NO-ASA and the subsequent appearance of quinone methide: an extremely reactive transient metabolite generated from the benzene linker (35) (36) (37) . Quinone methides are highly reactive with nucleotides in DNA, among other biologically relevant molecules (38) . The remarkably short lifetime of quinone methide intermediates complicates direct experimental assessment (35, 36) .
It has been reported that quinone methides react with cellular pools of glutathione and thioredoxin, depleting their levels and contributing to oxidative stress (39, 40) . Treatment of TK6 cells with NO-ASA resulted in H2AX phosphorylation and activation of ATM, indicative of doublestrand breaks (41) (42) (43) . NO-ASA also induced 8-oxoguanine lesions, indicative of increased levels of oxidative stress, in both LoVo and LRWZ cells (42, 44) . Based on these observations we regard it likely that treatment with high-dose NO-ASA induced sustained levels of DNA damage, which may not be adequately repaired in an Msh2-deficient background. The absence of tumors in NO-ASA treated wild-type mice, as well as the lack of tumors originating at extra-intestinal Msh2-proficient tissues of our LS/HNPCC mouse model support this hypothesis.
Treatment with 72 mg/kg NO-ASA was initiated after it became apparent that 720/1500 mg/kg treatments induced tumorigenesis and following published reports of potential toxicity (16) .
These subsequent studies were performed to estimate a lower limit of toxicity in our LS/HNPCC mouse model. A regime of 72 mg/kg NO-ASA is equimolar to that of 40 mg/kg for ASA. To our knowledge, ASA has not demonstrated comparable efficacy when administered at such low doses on MSI or tumorigenesis in any animal model. It was completely unexpected that such a low NO-ASA dose would improve survival (Fig. 1) . Like ASA, NO-ASA exhibits pleoitropic effects on cellular signaling pathways, which include induction of oxidative stress, inhibition of Wnt signaling, Cancer Research.
on January 6, 2018. © 2011 American Association for cancerpreventionresearch.aacrjournals.org Downloaded from activation of the mitogen-activated protein kinase (MAPK) pathway, and inhibition of inducible nitric oxide synthase and inhibition of NF-κB (45) . This effect appears unique to the LS/HNPCC genotype and has led to studies that explore the specific effect(s) of the NO-linker on MSI, which should ultimately result in better NO-ASA agents.
A key prediction from earlier data was that both ASA and NO-ASA might attenuate MSI in the intestinal tissues of Msh2-deficient mice (22, 23) . In fact, high dose NO-ASA treatment appeared to contribute to further instability as persistent MSI was detected in both normal and tumor intestinal tissues ( Fig. 3E+F ; Table 2 ). Small-pool PCR analysis of the same tissues supported this observation (Fig. 4E+F) . Furthermore, despite promoting animal survival, low dose NO-ASA did not appear to have a significant effect on MSI in the intestinal compartment. In contrast, ASA appeared to skew the total comparative MSI-H towards MSI-L when assessed in the context of the untreated control group ( Fig. 4D ; Table 2 ). These results are consistent with previous cellular data (22, 23) further refinements which may align its resultant tumor phenotype more exactly with that arising in LS/HNPCC patients. Treatment with azoxymethane/dextran sodium sulphate (AOM/DSS) can be used to expand the tumor incidence to the colon (47) . It is also possible to restrict Msh2 deletion to only the colon using a recently reported surgical procedure to physically limit subsequent infection of a Cre expressing adenovirus (48) .
Recent clinical trials report that regular aspirin use is associated with a lower risk of cancerspecific mortality in individuals already diagnosed with colorectal (49) or breast cancer (50) . The prevailing consensus is that the chemopreventive benefits of aspirin only manifest after ten years or longer of continuous administration (3, 4) . Our LS/HNPCC mouse data indicates that ASA and low dose NO-ASA requires continuous long-term treatment, with a subsequent 18-21% increase in lifespan. Considering that these animals are homozygous nulls for Msh2 (in the intestine), whereas LS/HNPCC patients are heterozygous for MMR defects and require a "second-hit" to promote tumorigenesis, this increase could translate into a dramatic difference in age-of-onset. Indeed, recently disclosed data suggest that long-term ASA treatment of LS/HNPCC patients appears to result in a 50% decrease in tumor incidence (J. Burn, personal communication). Table 1 
